

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

CD8

RRID:AB_2075537

Type: Antibody

Proper Citation

Agilent Cat# M7103, RRID:AB_2075537

Antibody Information

URL: http://antibodyregistry.org/AB_2075537

Proper Citation: Agilent Cat# M7103, RRID:AB_2075537

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Used By NYUIHC-16. Original Manufacturer: Dako. Now part of Agilent. Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: CD8

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: C8/144B

Antibody ID: AB_2075537

Vendor: Agilent

Catalog Number: M7103

Record Creation Time: 20250820T042357+0000

Record Last Update: 20250820T185205+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 84 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Spalato Ceruso M, et al. (2026) Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1887.

Pham FK, et al. (2026) Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy. Journal for immunotherapy of cancer, 14(6).

Mandal G, et al. (2026) Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression. iScience, 29(8), 116757.

Yu KKH, et al. (2026) Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression. Cancer cell, 44(1), 129.

Hernández-Verdin I, et al. (2026) GABA promotes resistance to immunotherapy in patients with TLS-positive tumors. Cancer cell.

Schlaak M, et al. (2026) MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(14), 2921.

Sobu R, et al. (2026) IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. iScience, 29(7), 116386.

Niravath P, et al. (2026) A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1697.

Gobbini E, et al. (2025) The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma. *Cancer immunology research*, 13(4), 517.

Carneiro BA, et al. (2025) Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors. *Cancer research communications*, 5(3), 444.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

Yamamoto N, et al. (2025) HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(4), 733.

Huyghe N, et al. (2025) Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan. *Cell reports. Medicine*, 6(7), 102201.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. *Cancer research communications*, 5(9), 1530.

Stockem CF, et al. (2025) Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3897.

Damle SR, et al. (2025) Intratumoral three-cell-type clusters are a conserved feature of endogenous antitumor immunity. *Cancer immunology research*.

Wu SG, et al. (2025) Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. *Clinical and translational medicine*, 15(1), e70149.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

Bechter O, et al. (2025) A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(12), 2358.

Alcindor T, et al. (2025) Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response. *Cell reports. Medicine*, 6(4), 102045.